The estimated Net Worth of Richard Scott Struthers is at least 26.1 百万$ dollars as of 8 May 2024. Richard Struthers owns over 107,448 units of Crinetics Pharmaceuticals Inc stock worth over 18,516,700$ and over the last 6 years Richard sold CRNX stock worth over 7,582,778$.
Sign up
Richard Struthers CRNX stock SEC Form 4 insiders trading
Richard has made over 15 trades of the Crinetics Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Richard exercised 107,448 units of CRNX stock worth 997,117$ on 8 May 2024.
The largest trade Richard's ever made was exercising 200,000 units of Crinetics Pharmaceuticals Inc stock on 2 November 2023 worth over 1,856,000$. On average, Richard trades about 31,180 units every 70 days since 2019. As of 8 May 2024 Richard still owns at least 364,933 units of Crinetics Pharmaceuticals Inc stock.
You can see the complete history of Richard Struthers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Richard Struthers's mailing address?
Richard's mailing address filed with the SEC is C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO, CA, 92121.
Insiders trading at Crinetics Pharmaceuticals Inc
Over the last 6 years, insiders at Crinetics Pharmaceuticals Inc have traded over 52,514,606$ worth of Crinetics Pharmaceuticals Inc stock and bought 3,613,259 units worth 62,800,483$ . The most active insiders traders include Advisors Llcperceptive Life...、Jack Nielsen、Capital Viii, Llc Vivo Capi.... On average, Crinetics Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of 3,116,248$. The most recent stock trade was executed by Stephen F. Betz on 26 August 2024, trading 3,000 units of CRNX stock currently worth 159,570$.
What does Crinetics Pharmaceuticals Inc do?
neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.
What does Crinetics Pharmaceuticals Inc's logo look like?
Complete history of Richard Struthers stock trades at Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc executives and stock owners
Crinetics Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
R. Scott Struthers,
President, Chief Executive Officer, Director -
Alan Krasner,
Chief Medical Officer -
Marc Wilson,
Chief Financial Officer -
Dr. R. Scott Struthers Ph.D.,
Founder, Pres, CEO & Director -
Dr. Ajay Madan DABT, Ph.D., D.A.B.T.,
Chief Devel. Officer -
Marc J. C. Wilson,
CFO & Sec. -
Stephanie Okey,
Independent Director -
Wendall Wierenga,
Independent Chairman of the Board -
Matthew Fust,
Independent Director -
Jeff E. Knight,
Chief Operating Officer -
Stephen Kaldor,
Independent Director -
Weston Nichols,
Independent Director -
Peter Trainer,
Vice President - Clinical Endocrinology -
Camille Bedrosian,
Independent Director -
Adriana Cabre,
Vice President of Human Resources -
Ajay Madan,
Chief Development Officer -
Chris Robillard M.B.A.,
Chief Bus. Officer -
James Hassard,
Chief Commercial Officer -
Dr. Alan S. Krasner M.D.,
Chief Medical Officer -
Adriana Cabre M.B.A.,
Chief HR Officer -
Kevin Capps,
Head of Intellectual Property -
Dr. Alan S. Krasner,
Chief Medical Officer -
Garlan Adams,
Gen. Counsel -
Dr. Stephen F. Betz Ph.D.,
Founder & Chief Scientific Officer -
Dr. Yun-Fei Zhu,
Founder & VP of Chemistry -
Jeff E. Knight,
Chief Operating Officer -
Advisors Llcperceptive Life...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
Venture Capital V, L.P.Vers...,
-
Capital Viii, Llc Vivo Capi...,
-
James Hassard,
Chief Commercial Officer -
Jack Nielsen,
Director -
Coelho Rogerio Vivaldi,
-
Dana Pizzuti,
Chief Med and Dev Officer -
Stephen F. Betz,
Chief Scientific Officer -
Caren Deardorf,